LEXEO Message to the Friedreich Ataxia Community

Message to the Friedreich Ataxia Community. October 7, 2025​.

This morning, we were pleased to share positive interim clinical data for LX2006, our investigational gene therapy, that includes both cardiac and neurological outcome measures. LX2006 (AAVrh10hFXN) is currently being studied in the Lexeo-sponsored SUNRISE-FA Phase 1/2 clinical trial and the Weill Cornell Medicine investigatorinitiated Phase 1A trial for the treatment of Friedreich ataxia cardiomyopathy.

LEXEO Message to the Friedreich Ataxia Community